Your browser doesn't support javascript.
loading
Remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule
Arbo, Antonio; Falleiros-Arlant, Luiza Helena; López, Eduardo L; Brea del Castillo, José; Martínez de Cuellar, Celia; Moreno, Gabriela; Rolón, Roger; Cerda, Javier; Eguiazú, Salim.
Afiliação
  • Arbo, Antonio; s.af
  • Falleiros-Arlant, Luiza Helena; s.af
  • López, Eduardo L; s.af
  • Brea del Castillo, José; s.af
  • Martínez de Cuellar, Celia; s.af
  • Moreno, Gabriela; s.af
  • Rolón, Roger; s.af
  • Cerda, Javier; s.af
  • Eguiazú, Salim; s.af
Rev. chil. infectol ; 36(1): 83-90, feb. 2019. tab
Artigo em Inglês | LILACS | ID: biblio-1003656
Biblioteca responsável: CL1.1
ABSTRACT
Abstract Given that the last notified case of poliomyelitis due to wild poliovirus type 2 was in 1999, in 2012, the Strategic Advisory Group of Experts on Immunization (SAGE) of the World Health Organization (WHO) recommended the withdrawal of the type 2 component of oral polio vaccine (OPV) and the introduction of a bivalent OPV (bOPV) in all countries by 2016. WHO recommended also that the withdrawal should be preceded by the introduction of at least one dose of inactivated poliovirus vaccine (IPV) in routine immunization schedules. The introduction of IPV prior to the change of the bOPV in 2016 to trivalent OPV (tOPV) was based on the concept of ensuring that a substantial proportion of the population would be protected against type 2 polio after the removal of the type 2 OPV. However, the world's two producers of IPV (Bilthoven Biologicals and Sanofi) have faced problems in the production of this vaccine and therefore reported a reduction of the global supply of IPV. In response to the potential shortage of IPV, at a meeting held on March 10 2017, the SAGE and Technical Advisory Group (TAG) of the Pan American Health Organization (PAHO) urged the countries in the Latin American region to replace the routine administration of the full doses of inactivated polio vaccine (IPV-C) in the immunization schedule (administered by intramuscular route), administering a fraction of the full dose in two intradermal shots (IPV-f). The possibility of this strategy was analyzed by opinion leaders convened by the Paraguayan Society of Pediatrics with the support of the Latin American Society of Pediatric Infectious Diseases (SLIPE) and Latin American Association of Pediatrics (ALAPE). This document presents the results of the discussion.
Assuntos

Texto completo: Disponível Coleções: Bases de dados internacionais Contexto em Saúde: ODS3 - Saúde e Bem-Estar Problema de saúde: Meta 3.8 Atingir a cobertura universal de saúde / Meta 3.3: Acabar com as doenças tropicais negligenciadas e combater as doenças transmissíveis Base de dados: LILACS Assunto principal: Poliomielite / Vacina Antipólio de Vírus Inativado / Esquemas de Imunização / Vacinação Tipo de estudo: Estudo de etiologia / Fatores de risco Limite: Criança / Humanos Idioma: Inglês Revista: Rev. chil. infectol Assunto da revista: Doenças Transmissíveis Ano de publicação: 2019 Tipo de documento: Artigo

Texto completo: Disponível Coleções: Bases de dados internacionais Contexto em Saúde: ODS3 - Saúde e Bem-Estar Problema de saúde: Meta 3.8 Atingir a cobertura universal de saúde / Meta 3.3: Acabar com as doenças tropicais negligenciadas e combater as doenças transmissíveis Base de dados: LILACS Assunto principal: Poliomielite / Vacina Antipólio de Vírus Inativado / Esquemas de Imunização / Vacinação Tipo de estudo: Estudo de etiologia / Fatores de risco Limite: Criança / Humanos Idioma: Inglês Revista: Rev. chil. infectol Assunto da revista: Doenças Transmissíveis Ano de publicação: 2019 Tipo de documento: Artigo
...